




TRPP Alberta

ANNUAL REPORT
2020-2021

Administered by CPSA, TPP Alberta is a partnership between the following member organizations:



TPP Alberta: About the Program

TPP Alberta uses data to optimize safe patient care. Since 1986, we have monitored the use of prescription drugs prone to misuse.

TPP Alberta's mandate is to:

- Monitor prescribing, dispensing and utilization practices regarding TPP-targeted medications.
- Provide timely and relevant information on TPP-targeted medications to prescribers, dispensers, consumers, regulatory bodies, Member Organizations and stakeholders.
- Work with Member Organizations and stakeholders to enable system-level change, to ensure appropriate use of targeted medications.
- Ensure efficient and effective functioning of TPP Alberta.

TPP Alberta: 2020-2021 Highlights

TPP Medication List Changes

The TPP Alberta Steering Committee approved several medication list changes, including the following (please note the list below is not exhaustive of all changes):

Sublocade (injectable) and **Probuphine** (implant), long-acting formulations of buprenorphine, were moved from Type 1 to Type 2 in February 2021. They are typically used for treatment of Opioid Use Disorders and are administered directly by a healthcare professional.

To do our part in supporting appropriate antibiotic use, TPP Alberta formally added **Antibiotics** to the Type 2 drug list in February 2021.

Prescription-status oral liquids containing codeine were moved from Type 2 to Type 1 TPP status in July 2020 to improve prescribing oversight and help address public safety concerns associated with non-medical/recreational use, diversion and prescription forgeries.

TPP Alberta	
List of Monitored Medications	
Please refer to the Veterinary Specific Medications List for Veterinary prescription requirements.	
Type 1 Medications <i>(Secure prescription form required)</i>	February 2021
Buprenorphine <ul style="list-style-type: none">- BuTrans- Vetergesic	Ketamine* <ul style="list-style-type: none">- Ketalar- Ketalean- Ketaset- Narketan
Butalbital Preparations <ul style="list-style-type: none">- Fiorinal- Fiorinal C ¼ & C ½- Teva-Tecnal C ¼ & C ½	Meperidine – Pethidine <ul style="list-style-type: none">- Demerol- Meperidine HCl Injection
Butorphanol <ul style="list-style-type: none">- Apo-Butorphanol- Dolorex- Stadol- Torbutrol- Torbugesic	Methodone <p><i>Only authorized physicians may prescribe methadone for opioid use disorder. Visit the CPSA OAT Program page for more information. Authorization of physicians is not required when methadone is prescribed for pain.</i></p> <ul style="list-style-type: none">- Metadol- Methadose
Codeine <p><i>Applies to prescription status, codeine-containing oral liquids.</i></p> <ul style="list-style-type: none">- PMS-Acetaminophen with Codeine Elixir- Calmylin ACE- Coactifed- Dimetane C Expectorant- Dimetapp C- Robitussin AC- Teva-Cotridin Expectorant- Teva-Cotridin- Codeine Phosphate Syrup- Linctus Codeine Blanc	Methylphenidate <p><i>Exceptions: Biphentin, Concerta and Fozquest brands of methylphenidate are Type 2 TPP Alberta drugs and do not require use of a TPP prescription form.</i></p> <ul style="list-style-type: none">- PMS Methylphenidate/ER- Ritalin
Dextropropoxyphene	Morphine <ul style="list-style-type: none">- Doloral- Kadian- M-Esion- Morphine Epidural- Morphine Sulfate SR- M.O.S.- MS Contin- Statex
Esketamine <ul style="list-style-type: none">- Spravato	Normethadone <ul style="list-style-type: none">- Cophylac
Fentanyl/Sufentanil/Alfentanil <ul style="list-style-type: none">- Alfentanil Injection- Duragesic Patches- Sufentanil Citrate Injection	Oxycodone <ul style="list-style-type: none">- Oxy-IR- OxyNEO- Supeudol- Targin- Teva-Oxycocet/Oxycodan
Hydrocodone-Dihydrocodeinone <ul style="list-style-type: none">- Novahistex-DH- Novahistine-DH- PDP Hydrocodone- Tussionex	Pentazocine <ul style="list-style-type: none">- Talwin
Hydromorphone-Dihydromorphinone <ul style="list-style-type: none">- Dilaudid- Hydromorph Contin	Tapentadol <ul style="list-style-type: none">- Nucynta IR/Extended Release

TPP Alberta: 2020-2021 Highlights

Program Evolution:

Communication

Resources and information were shared regularly with prescribers, dispensers and stakeholders through emails, newsletters and online resources.

Collaboration

Partnered with the Alberta College of Pharmacy to disseminate information on the exemptions to the *Controlled Drugs and Substances Act* (CDSA), allowing patients to receive uninterrupted care during the pandemic.

Contract Update for Secure Forms

RFP process resulted in a new negotiated contract with an estimated annualized savings of \$40,000 for TPP pad printing and distribution costs.


COVID-19 Impact

Due to limited ability to process mail and access records for manual data entry, infrastructure was revised and a new process rolled out to allow secure entry by staff members working remotely.

TPP staff members volunteered to process incoming mail and scan records at the office. Additional resources were required to catch up on the data-backlog created during the initial office closure.

COVID-19-specific guidance documents were developed and disseminated through online and other means of communications, including joint advice for prescribers/dispensers.

TPP Alberta: 2020-2021 Highlights



Data Utilization:

TPP Annual Report

Released the latest TPP Annual Report, highlighting a comprehensive summary of program activities.

TPP Alberta Atlas:

Released the latest TPP Alberta Atlas (2019), highlighting provincial use of opioids and benzodiazepines monitored by TPP Alberta.

TPP Alberta Antibiotic Atlas:

Released the latest TPP Alberta Antibiotic Prescribing Atlas (2019), highlighting provincial use of antibiotics monitored by TPP Alberta.

TPP Alberta: Data Utilization

MD snapshot

NP Snapshot

MD & NP Snapshot: Prescribing Reports

Personalized reports based on TPP data and focusing on evidence-informed thresholds were produced and disseminated by CPSA and CARNA quarterly to more than 9,000 physicians and over 350 nurses who prescribed opioids and benzodiazepine / Z-drugs.



Data Quality Intervention

An educationally-focused TPP initiative, the Data Quality Intervention provides guidance to pharmacies submitting data to PIN where an error is identified. A joint CPSA/ACP notification was sent to 56 pharmacies under DQI. TPP also provides facilitation to support correction of data errors, directly contributing to PIN Data Quality.



Mentorship & Education

The Daily Oral Morphine Equivalent (DOME) Program identified prescribers who had patients with very high OME values and paired them with an educational mentor.

TPP Antibiotic Atlas Trends

Prescriber Type	Prescriptions	Patients	Prescribers*	% Unkown Prescribers
Physician	2,075,026	1,212,235	12,272	3.3%
Dentist	284,604	219,526	–	97.1%
Pharmacist	124,462	107,465	4,006	0.2%
Nurse Practitioner	23,285	18,166	480	11.5%
Unknown	19,273	15,503	–	100.0%
Optometrist	3,385	2,982	–	96.1%
Dental Hygienist	314	272	–	99.4%
Dietician	109	100	–	100.0%

Patients by Prescriber Type 2019

* Unknown Prescribers shows the percentage of prescriptions from prescribers who cannot be identified due to lack of use (or access to) unique prescriber identifiers.

Prescriptions by Antibiotic per Year 2017-2019



Antibiotic	2017	2018	2019	Trend 2017–2019	2019
Amoxicillin	686,312	668,543	692,063		
Azithromycin	255,195	265,497	291,382		
Cephalexin	236,491	240,437	244,664		
Amox-Clav	193,343	201,491	213,053		
Ciprofloxacin	174,244	166,048	153,619		
Nitrofurantoin	125,633	130,640	140,574		
Doxycycline	109,977	120,527	131,887		
Metronidazole	92,551	95,678	98,623		
Clarithromycin	129,815	108,421	95,313		
Clindamycin	86,318	83,964	80,751		

* Only the most commonly-prescribed antibiotics are shown, representing over 84% of all oral antibiotics dispensed.

TPP Antibiotics Atlas Trends

Distribution of Prescriptions per Patient 2019

*8% or more patients were dispensed two or more prescriptions for the same antibiotic in a year.




Average Treatment Days per Prescription 2019


*Treatment days per prescription of more than seven days was common for most antibiotics other than azithromycin.

TPP Alberta Atlas Prescribing

Opioid Prescribers 2019



Opioid Prescriptions 2019



*Prescriptions sum does not match the summary value because only the four major prescriber types are shown. Other known prescriber types are associated with 245 prescriptions (Opticians 127, Dental Hygienists 71, Dieticians 46, and Podiatrists 1).

12,526 prescriptions have no prescriber type identified. Also, there are instances where no specified prescriber is identified within the shown groups; i.e., 2% of prescriptions by physicians, 1% by pharmacists, 96% by dentists and 5% by nurse practitioners have an unidentified prescriber. (Please note the previous 2019-2020 TPP Annual Report had a printing error and stated the prescriber breakdown data was from 2019, when it should have read 2018.)

TPP Alberta Atlas Trends - Opioids


Year	Prescriptions	Patients	Prescribers	Pharmacies	Population	OME per day per 1000 Population	Patients per 1000 Population	Patients ≥90 OME per 1000 Population
2015	1,941,252	628,762	13,767	1,544	4,196,192	1,667	149.8	3.7
2016	2,031,450	654,616	14,789	1,583	4,252,720	1,637	153.9	3.7
2017	1,934,117	634,301	15,330	1,387	4,285,997	1,431	148.0	3.2
2018	1,769,768	597,055	15,215	1,476	4,306,822	1,260	138.6	2.8
2019	1,664,853	573,104	14,908	1,533	4,371,154	1,195	131.1	2.6
5 year trend								

Use of Prescription Opioids in Alberta

.....
2015-2019

Five-Year Trends in Areas with Highest Rates of Total OME per Day


.....
2015-2019




*Decreases in average OME rates/day are also being seen in areas of the province with high opioid prescribing.

TPP Alberta Atlas Prescribing

Benzodiazepine Prescribers 2019



Benzodiazepine Prescriptions 2019




* Prescriptions sum does not match the summary value because only the four major prescriber types are shown. 104 prescriptions are associated with other known prescriber types (Opticians 78, Dieticians 17, Dental Hygienists 9).

5,879 prescriptions have no prescriber type identified. Within the four main prescriber types, specific prescribers are not identified for 1% of prescriptions by physicians, < 1% by pharmacists, 96% by dentists and 7% by nurse practitioners. (Please note the previous 2019-2020 TPP Annual Report had a printing error and stated the prescriber breakdown data was from 2019, when it should have read 2018.)

TPP Alberta Atlas Trends - Benzodiazepines

Use of Prescription Benzodiazepines in Alberta 2015-2019


Year	Prescriptions	Patients	Prescribers	Pharmacies	DDD's per 1000 Population	Patients per 1000 Population	Patients ≥ 2 DDD's	Patients ≥ 2 DDD's per 1000 Population
2015	1,220,487	373,641	12,033	1,345	41.6	89.0	15,186	3.6
2016	1,284,642	386,883	12,738	1,418	41.0	91.0	14,728	3.5
2017	1,204,418	369,828	13,151	1,385	36.6	86.3	12,257	2.9
2018	1,127,665	355,901	13,399	1,468	33.6	82.6	10,773	2.5
2019	1,057,581	343,277	13,379	1,530	30.8	78.5	9,825	2.2
5 year trend								




Five-Year Trends for Five Areas with Highest Rates of Elderly Benzodiazepine Patients 2015-2019

* In addition to a general downward trend in benzodiazepine prescriptions and DDDs in the province, a decrease in the number of elderly patients receiving benzodiazepines is seen in the majority of areas with high prescribing rates.

TPP Alberta 2015-2021: OME* Rates/1,000



TPP Alberta 2015-2021: Benzodiazepine & Z-drug Rates/1,000




TPP Alberta Atlas Veterinarian Prescriptions


Veterinarian prescriptions for animal clients are monitored by TPP Alberta, as there is a potential for misuse by the human owners of the animal patients. Veterinarian prescriptions for animals were not included in the overall analyses of opioid & benzodiazepine utilization.

Opioid Prescriptions 2019

Main Ingredient	Prescriptions
Tramadol	10,142
Buprenorphine	5,574
Hydrocodone	3,726
Codeine	1,395
Butorphanol	519
Other ingredients	526



Main Ingredient	Prescriptions
Alprazolam	928
Diazepam	835
Clorazepate Dipotassium	62
Lorazepam	40
Midazolam	38
Other ingredients	24



Benzodiazepine Prescriptions 2019

TPP Alberta Grant Report:

Financial Summary

		GAMS Grant ID			Grant-011405		
UNAUDITED FINANCIAL REPORTING FOR GRANTS							
MULTI-YEAR AGREEMENT							
Report #1							
YEAR 1 of 3							
Grant Recipient:	College of Physicians & Surgeons of Alberta						
Description of Grant:	TPP Alberta						
Term of Agreement:	01-Apr-20	to	31-Mar-23	Date:	17-May-21		
Financial Reporting for the Period:	01-Apr-20	to	31-Mar-21				
	Current Fiscal Period:			Full Term of Agreement			
	Year-To-Date			Agreement-To-Date			
	Budget	Actuals	Variance	Budget	Actuals	Variance	
	12 months	12 months		12 months	12 months		
Revenue							
Contribution from Alberta Health (Surplus)	30,417.39	30,417.39	-	30,417.39	30,417.39	-	
Contribution from Alberta Health Government Grant - Investment Income	658,836.61	658,836.61	-	658,836.61	658,836.61	-	
Grant - Other Sources	-	184.17	184.17	-	184.17	184.17	
CPSA Contribution	127,400.00	127,400.00	-	127,400.00	127,400.00	-	
	175,614.00	175,867.00	253.00	175,614.00	175,867.00	253.00	
Total Revenue	992,268.00	992,705.17	437.17	992,268.00	992,705.17	437.17	
Expense							
General Program Expenditures							
Consulting	248,213.00	168,262.50	(79,950.50)	248,213.00	168,262.50	(79,950.50)	
Legal	750.00	138.60	(611.40)	750.00	138.60	(611.40)	
Occupancy Costs	25,350.00	25,200.00	(150.00)	25,350.00	25,200.00	(150.00)	
Operating Costs	60,252.00	60,224.00	(28.00)	60,252.00	60,224.00	(28.00)	
Printing, Supplies & Courier	15,687.00	2,718.18	(12,968.82)	15,687.00	2,718.18	(12,968.82)	
Special printing	362,499.00	356,810.86	(5,688.14)	362,499.00	356,810.86	(5,688.14)	
Travel, Meals & Accommodation	-	-	-	-	-	-	
Sub-total	712,751.00	613,354.14	(99,396.86)	712,751.00	613,354.14	(99,396.86)	

TPP Alberta Grant Report: Financial Summary Con't

Staffing Costs						
Salaries & Benefits	275,723.00	231,089.38	(44,633.62)	275,723.00	231,089.38	(44,633.62)
Professional Development	3,670.00	419.83	(3,250.17)	3,670.00	419.83	(3,250.17)
Sub-total	279,393.00	231,509.21	(47,883.79)	279,393.00	231,509.21	(47,883.79)
Committee Expenses						
Telephone & Fax	124.00	-	(124.00)	124.00	-	(124.00)
Sub-total	124.00	-	(124.00)	124.00	-	124.00
Total Expenses						
	992,268.00	844,863.35	(147,404.65)	992,268.00	844,863.35	(147,404.65)
Surplus < Deficit >						
	-	147,841.82	147,841.82	-	147,841.82	147,841.82
Unexpended Funding						
<input type="checkbox"/> Attached Request(s) for Retention of Unexpended Funding Form (FINAL YEAR ONLY)	Opening Balance: Prior Year's <Deficit>		Year 1			-
	Add (Subtract) Current Surplus/ (Deficit):		12 months (April 2020 - March 2021)			147,841.82
	Less: Approved Request(s) for Retention of Unexpended Funding (FINAL YEAR ONLY)					
	Closing Balance: <Deficit>		31-Mar-21			147,841.82
Finance Contact:			Program Contact:			
Josh Eberhart	780-401-0987	Ed Jess		(780) 969-4946		
Name	Phone #	Name		Phone #		
Finance Approval:						
Tracy Simons	Chief Financial Officer	19-May-21		Tracy Simons		
Name	(780) 969-4983	Date		Signature		
	Position / Phone #			<small>Digitally signed by Tracy Simons DN: dc=lan, dc=cpsa, ou=CPSA, ou=Users, cn=Tracy Simons Date: 2021.05.20 12:37:04 -0600</small>		

TPP Alberta: Resources

TPP Alberta Website (cpsa.ca/tpp)

TPP Alberta Medication List

TPP Alberta Guide

2019 TPP Alberta Atlas

2019 TPP Alberta Antibiotic Atlas

TPP Alberta

TPP Alberta is about using data to optimize safe patient care. Since 1986, we have been monitoring the use of prescription drugs prone to misuse in the province.

[TPP Alberta Program Guide](#)



TPP Alberta Medication List

See and download the list

[See the list >](#)



Veterinary-Specific Medications List

See and download the list

[See the list >](#)



TPP Alberta COVID-19 Guidance

Resources & guidance

[See guidance >](#)